We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

14 hedge funds and large institutions have $6.65M invested in Gain Therapeutics in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.01% less ownership

Funds ownership: 7.53% → 7.51% (-0.01%)

26% less capital invested

Capital invested by funds: $8.95M → $6.65M (-$2.3M)

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TI
Telemetry Investments
New York
+$551K
2
CM
CM Management
Florida
+$454K
3
IAP
Indie Asset Partners
Indiana
+$248K
4
V
Veritable
Delaware
+$209K
5
UBS Group
UBS Group
Switzerland
+$22.1K

Top Sellers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
-$1.56M
2
Millennium Management
Millennium Management
New York
-$239K
3
BlackRock
BlackRock
New York
-$1.53K
4
Wells Fargo
Wells Fargo
California
-$8
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$4.07M – – –
TI
2
Telemetry Investments
New York
$716K +$551K +65,939 +218%
CM
3
CM Management
Florida
$479K +$454K +54,327 +543%
PCM
4
Prelude Capital Management
New York
$433K – – –
BCM
5
Bridgeway Capital Management
Texas
$372K – – –
IAP
6
Indie Asset Partners
Indiana
$221K +$248K +29,652 New
V
7
Veritable
Delaware
$187K +$209K +25,064 New
BlackRock
8
BlackRock
New York
$85K -$1.53K -183 -2%
UBS Group
9
UBS Group
Switzerland
$51K +$22.1K +2,640 +64%
BCV
10
Banque Cantonale Vaudoise
Switzerland
$22K – – –
Morgan Stanley
11
Morgan Stanley
New York
$6K – – –
TRCT
12
Tower Research Capital (TRC)
New York
$4K +$4.04K +483 +671%
SPIA
13
Steward Partners Investment Advisory
New York
$1K – – –
GPCM
14
Granite Point Capital Management
Massachusetts
– -$1.56M -155,709 Closed
Millennium Management
15
Millennium Management
New York
– -$239K -23,878 Closed
Wells Fargo
16
Wells Fargo
California
– -$8 -1 -4%

GANX Hedge Fund Activity: Q3 2021 in Review

14 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2021, worth a combined $6.65M — down 26% from $8.95M a quarter earlier.

Fund positioning in GANX was balanced in Q3 2021: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 2 trimmed.

The largest buyer was Telemetry Investments, adding an estimated $551K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $1.56M sold.

  • 14 institutional investors held Gain Therapeutics (GANX) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $6.65M of Gain Therapeutics stock for Q3 2021, down 26% quarter-over-quarter.
  • 2 funds opened new Gain Therapeutics positions in Q3 2021 and 2 closed out, a net change of 0 holders.
  • The largest Gain Therapeutics buyer in Q3 2021 was Telemetry Investments, an estimated $551K added.
  • The largest Gain Therapeutics seller in Q3 2021 was Granite Point Capital Management, an estimated $1.56M sold.

Based on aggregated 13F filings for Q3 2021.